Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Gmbh

Gerhard Bodo

Ingrid Maurer-Fogy

Edgar Falkner

Rudolf Hauptmann

Peter Swetly

Gunther R Adolf

Peter Meindl

Christiaan Maria Reutelingsperger

Christian Stratowa

Ernest Cullen

Tilman Voss

Hans Tuppy

Silvia J Lindner-Frimmel

Silvia J Lindner

This invention relates to biologically active proteins, the DNA molecules coding for them, processes for preparing them and their use.

Vascular anticoagulant proteins DNA which codes them, processer for

Methods and vectors for expressing interferon-alpha (IFN-.alpha.) proteins in E. coli are provided. Use of a vector comprising an IFN-.alpha. sequence fused to an E. coli heat-stable enterotoxin signal sequence (STII) under the control of the E. coli phosphatase (phoA) promoter affords high levels of correctly-folded and -processed, biologically active IFN-.alpha. polypeptides.

Process and vector for expressing alpha-interferon in E. coli

The present invention relates to processes for purifying annexines. The overall process includes the steps of preparing a homogenized cell preparation and adjusting the pH to about 8.0 to 10.0, adding at least one bivalent cation, adding a phospholipid, washing the insoluble cell residue to remove the soluble constituents, and extracting the annexines from the cell residue with a chelating agent. This process initially promotes the adsorption of the annexines onto the insoluble cell residue or membrane of the host organism. The adsorption step makes it possible to eliminate unwanted soluble matter from the homogenized material by simple washing. Desorption is accomplished by using a chelating agent.

Process for purifying annexines

A process for the preparation and purification of recombinant Interferon-.alpha. is disclosed. The invention is directed to a process comprising the following steps: cultivating E. coli containing the interferon gene for a growth period during which not more than 5% methionine-interferon is formed; extracting and concentrating the expressed interferon; subjecting the preliminarily purified material to Tandem Chromatography, wherein the Tandem Chromatography comprises separation on a cellulose column followed by an anti-alpha-interferon monoclonal antibody affinity column; subjecting the thus purified material to isoelectric precipitation of impurities at about pH 4.0 to about pH 4.8; and purifying the interferon by chromatography on a high performance cation exchange column using a volatile buffer, wherein the purified interferon is non-immunogenic when administered parenterally to a human.

Process for preparing and purifying alpha-interferon

This invention relates to new hybrid interferons consisting of part of an .alpha.-interferon and part of an omega interferon, the N-terminal Met or N-formyl-Met derivatives thereof and, if the peptide sequence of the hybrid interferon contains a glycosylation site, the N-glycosylated derivatives thereof, their use as pharmaceutical compositions and as intermediate products for immunizing experimental animals and processes for producing them,

Hybrid interferons, their use as pharmaceutical compositions and as

This invention is directed to a process of producing interferon which comprises incubating permanent cell lines of lymphoblast origin or human fibroblast cells with interferon inducers and stimulator substances and recovering the interferon produced.

Process for the production of human interferon

Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen or methyl,

Growing community of inventors

Vienna, Austria

Gerhard Bodo